Ovagen is a biotechnology company that has a developed a process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. The Ovagen team has a wealth of experience in the life sciences.

• Ovagen’s Research and Development team have 100 years of combined life sciences related R & D experience. Ovagen’s CEO’s previous venture was sold in 2002 to Charles River Laboratories Inc and the company’s operational team has a combined 75 years of life-science related experience.

• Ovagen has received patent protection in both Europe and the US for the process by which it produces GF eggs, further patent approvals are pending.

• Ovagen has achieved proof of concept (GF chickens have been bred through 3 generations) and funds have been raised for the construction of a production facility which will to produce the initial flocks of GF birds (for subsequent expansion into new large scale GF facilities) and GF eggs, initially for customer validation.
 

•The methods used by Ovagen are covered by significant IP protection for granted patents.

"The collaboration will allow further development of the Ovagen transgenic chicken platform for the generation of recombinant proteins to GMP standard.  Development of this technology will add value to Ireland's capability in the production of novel biotherapeutics."

Ian Shaw, Ovagen

More information from www.ovagen.ie